Inhibikase Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2025, on August 14, 2025. The company recorded a net loss of $9.9 million, or $0.11 per share, for the quarter.
This compares to a net loss of $5.0 million, or $0.66 per share, in the second quarter of 2024. Research and development expenses increased to $5.3 million for the quarter, up from $3.1 million in the prior year period.
Selling, general and administrative expenses also rose to $5.9 million, compared to $2.0 million in the second quarter of 2024. As of June 30, 2025, cash, cash equivalents, and marketable securities were $87.7 million, a decrease from $97.5 million at December 31, 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.